Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Clinical implications of elevated HIV-1 viral load results obtained from samples stored frozen in vacutainer plasma preparation tubes.

Cloherty G, Swanson P, Lucic D, Dieckhaus K, Anthony P, Cataline P, Herman C, Hackett J Jr, Skolnik PR, Chirch L.

J Virol Methods. 2014 Aug;204:91-2. doi: 10.1016/j.jviromet.2014.01.025. Epub 2014 Apr 16.

PMID:
24747107
2.

Patient and provider perspectives on cellular phone-based technology to improve HIV treatment adherence.

Baranoski AS, Meuser E, Hardy H, Closson EF, Mimiaga MJ, Safren SA, Virk P, Luk R, Skolnik PR, Kumar VS.

AIDS Care. 2014 Jan;26(1):26-32. doi: 10.1080/09540121.2013.802282. Epub 2013 Jun 6.

3.

Development and field testing of an HIV medication touch screen computer patient adherence tool with telephone-based, targeted adherence counseling.

McInnes DK, Hardy H, Goetz MB, Skolnik PR, Brewster AL, Hofmann RH, Gifford AL.

J Int Assoc Provid AIDS Care. 2013 Nov-Dec;12(6):397-406. doi: 10.1177/1545109712454333. Epub 2012 Sep 11.

PMID:
22968353
4.

A low-effort, clinic-wide intervention improves attendance for HIV primary care.

Gardner LI, Marks G, Craw JA, Wilson TE, Drainoni ML, Moore RD, Mugavero MJ, Rodriguez AE, Bradley-Springer LA, Holman S, Keruly JC, Sullivan M, Skolnik PR, Malitz F, Metsch LR, Raper JL, Giordano TP; Retention in Care Study Group.

Clin Infect Dis. 2012 Oct;55(8):1124-34. Epub 2012 Jul 24.

5.

Acceptance of interferon-gamma release assay by a high-risk urban cohort.

O'Donnell MR, Coe A, Bliss C, Lee D, Tumilty S, Skolnik PR, Horsburgh CR Jr, Cotton D, Saukkonen J.

Int J Tuberc Lung Dis. 2011 Oct;15(10):1334-9. doi: 10.5588/ijtld.11.0029.

PMID:
22283891
6.

A collaborative awareness system for chronic disease medication adherence applied to HIV infection.

Moore JO, Hardy H, Skolnik PR, Moss FH.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:1523-7. doi: 10.1109/IEMBS.2011.6090367.

PMID:
22254610
7.

Randomized controlled trial of a personalized cellular phone reminder system to enhance adherence to antiretroviral therapy.

Hardy H, Kumar V, Doros G, Farmer E, Drainoni ML, Rybin D, Myung D, Jackson J, Backman E, Stanic A, Skolnik PR.

AIDS Patient Care STDS. 2011 Mar;25(3):153-61. doi: 10.1089/apc.2010.0006. Epub 2011 Feb 16.

8.

Incidence and predictors of acute kidney injury in an urban cohort of subjects with HIV and hepatitis C virus coinfection.

Garg S, Hoenig M, Edwards EM, Bliss C, Heeren T, Tumilty S, Walley AY, Koziel MJ, Skolnik PR, Horsburgh CR, Cotton D.

AIDS Patient Care STDS. 2011 Mar;25(3):135-41. doi: 10.1089/apc.2010.0104. Epub 2011 Feb 10.

9.

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G Jr, Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC Jr, Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL Jr, Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, Mcleod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O'Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC 3rd, Olender SA, Ostrowski M, Owen WF Jr, Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC 3rd, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM Jr, Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Telenti A, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, van't Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao M.

Science. 2010 Dec 10;330(6010):1551-7. doi: 10.1126/science.1195271. Epub 2010 Nov 4.

10.

Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.

Wilkin TJ, Su Z, Krambrink A, Long J, Greaves W, Gross R, Hughes MD, Flexner C, Skolnik PR, Coakley E, Godfrey C, Hirsch M, Kuritzkes DR, Gulick RM.

J Acquir Immune Defic Syndr. 2010 Aug;54(5):470-6.

11.

A 24-year-old patient with Crohn's disease starting immunosuppressive therapy: vaccination issues to consider.

Wasan SK, Skolnik PR, Farraye FA.

Clin Gastroenterol Hepatol. 2010 Dec;8(12):1013-6. doi: 10.1016/j.cgh.2010.07.001. Epub 2010 Jul 23. No abstract available.

PMID:
20656060
12.

A practical guide to vaccinating the inflammatory bowel disease patient.

Wasan SK, Baker SE, Skolnik PR, Farraye FA.

Am J Gastroenterol. 2010 Jun;105(6):1231-8. doi: 10.1038/ajg.2009.733. Epub 2010 Jan 26. Review.

PMID:
20104218
13.

Provider-focused intervention increases adherence-related dialogue but does not improve antiretroviral therapy adherence in persons with HIV.

Wilson IB, Laws MB, Safren SA, Lee Y, Lu M, Coady W, Skolnik PR, Rogers WH.

J Acquir Immune Defic Syndr. 2010 Mar;53(3):338-47. doi: 10.1097/QAI.0b013e3181c7a245.

14.

Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.

Su Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, Han D, Flexner C, Wilkin TJ, Skolnik PR, Greaves WL, Kuritzkes DR, Reeves JD; AIDS Clinical Trials Group A5211 Team.

J Infect Dis. 2009 Dec 1;200(11):1724-8. doi: 10.1086/648090.

15.

Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions.

Hosoya N, Su Z, Wilkin T, Gulick RM, Flexner C, Hughes MD, Skolnik PR, Giguel F, Greaves WL, Coakley E, Kuritzkes DR.

J Clin Microbiol. 2009 Aug;47(8):2604-6. doi: 10.1128/JCM.00632-09. Epub 2009 Jun 3.

16.

Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.

Tsibris AM, Paredes R, Chadburn A, Su Z, Henrich TJ, Krambrink A, Hughes MD, Aberg JA, Currier JS, Tashima K, Godfrey C, Greaves W, Flexner C, Skolnik PR, Wilkin TJ, Gulick RM, Kuritzkes DR.

Clin Infect Dis. 2009 Mar 1;48(5):642-9. doi: 10.1086/597007.

17.

Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.

Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, Rodriguez BA, Skowron G, Skolnik PR, Shafer RW, Pollard RB; AIDS Clinical Trials Group 384 Team.

Clin Infect Dis. 2009 Feb 1;48(3):350-61. doi: 10.1086/595888.

18.

Predictors of treatment for hepatitis C virus (HCV) infection in drug users.

Reed C, Stuver SO, Tumilty S, Nunes D, Murray JE, Graham CS, James Koziel M, Craven DE, Skolnik PR, Horsburgh CR Jr.

Subst Abus. 2008;29(1):5-15. doi: 10.1300/J465v29n01_02.

PMID:
19042314
19.

Patient risks, outcomes, and costs of voluntary HIV testing at five testing sites within a medical center.

Mehta SD, Hall J, Greenwald JL, Cranston K, Skolnik PR.

Public Health Rep. 2008 Sep-Oct;123(5):608-17.

20.

Human immunodeficiency virus infection alters tumor necrosis factor alpha production via Toll-like receptor-dependent pathways in alveolar macrophages and U1 cells.

Nicol MQ, Mathys JM, Pereira A, Ollington K, Ieong MH, Skolnik PR.

J Virol. 2008 Aug;82(16):7790-8. doi: 10.1128/JVI.00362-08. Epub 2008 Jun 4.

21.

The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV.

Vranceanu AM, Safren SA, Lu M, Coady WM, Skolnik PR, Rogers WH, Wilson IB.

AIDS Patient Care STDS. 2008 Apr;22(4):313-21. doi: 10.1089/apc.2007.0069.

PMID:
18338960
22.

Effect of a four-week course of interleukin-10 on cytokine production in a placebo-controlled study of HIV-1-infected subjects.

Pott GB, Sailer CA, Porat R, Peskind RL, Fuchs AC, Angel JB, Skolnik PR, Jacobson MA, Giordano MF, Lebeaut A, Grint PC, Dinarello CA, Shapiro L.

Eur Cytokine Netw. 2007 Jun;18(2):49-58. Epub 2007 Jun 26.

23.

Optimal recall period and response task for self-reported HIV medication adherence.

Lu M, Safren SA, Skolnik PR, Rogers WH, Coady W, Hardy H, Wilson IB.

AIDS Behav. 2008 Jan;12(1):86-94. Epub 2007 Jun 19.

PMID:
17577653
24.

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR; AIDS Clinical Trials Group 5211 Team.

J Infect Dis. 2007 Jul 15;196(2):304-12. Epub 2007 Jun 5.

PMID:
17570119
25.

Adult and pediatric emergency department sexually transmitted disease and HIV screening: programmatic overview and outcomes.

Mehta SD, Hall J, Lyss SB, Skolnik PR, Pealer LN, Kharasch S.

Acad Emerg Med. 2007 Mar;14(3):250-8.

26.

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM.

Clin Infect Dis. 2007 Feb 15;44(4):591-5. Epub 2007 Jan 17. Erratum in: Clin Infect Dis. 2007 May 15;44(10):1399.

PMID:
17243065
27.

Approaching the CDC's guidelines on the HIV testing of inpatients: physician-referral versus nonreferral-based testing.

Greenwald JL, Hall J, Skolnik PR.

AIDS Patient Care STDS. 2006 May;20(5):311-7.

PMID:
16706705
28.
29.

Tumor necrosis factor alpha leads to increased cell surface expression of CXCR4 in SK-N-MC cells.

Rostasy K, Gorgun G, Kleyner Y, Garcia A, Kramer M, Melanson SM, Mathys JM, Yiannoutsos C, Skolnik PR, Navia BA.

J Neurovirol. 2005 Jul;11(3):247-55.

PMID:
16036804
30.

Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.

Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, von Moltke LL.

Drug Metab Dispos. 2005 Jun;33(6):764-70. Epub 2005 Mar 11.

PMID:
15764714
31.

Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts.

Walensky RP, Losina E, Malatesta L, Barton GE, O'Connor CA, Skolnik PR, Hall JM, McGuire JF, Freedberg KA.

Am J Public Health. 2005 Jan;95(1):71-3.

32.

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

Mullins C, Eisen G, Popper S, Dieng Sarr A, Sankale JL, Berger JJ, Wright SB, Chang HR, Coste G, Cooley TP, Rice P, Skolnik PR, Sullivan M, Kanki PJ.

Clin Infect Dis. 2004 Jun 15;38(12):1771-9. Epub 2004 May 25.

PMID:
15227626
33.

Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection.

Hardy H, Skolnik PR.

Pharmacotherapy. 2004 Feb;24(2):198-211.

PMID:
14998221
34.

HIV therapy--what do we know, and when do we know it?

Skolnik PR.

N Engl J Med. 2003 Dec 11;349(24):2351-2. No abstract available.

PMID:
14668462
35.

Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects.

Skolnik PR, Rabbi MF, Mathys JM, Greenberg AS.

J Acquir Immune Defic Syndr. 2002 Sep 1;31(1):1-10. Erratum in: J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):657.

PMID:
12352144
36.

Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men.

Roubenoff R, Grinspoon S, Skolnik PR, Tchetgen E, Abad L, Spiegelman D, Knox T, Gorbach S.

Am J Physiol Endocrinol Metab. 2002 Jul;283(1):E138-45.

37.

Discordant Human Immunodeficiency Virus Type 1 drug resistance mutations, including K103N, observed in cerebrospinal fluid and plasma.

Tashima KT, Flanigan TP, Kurpewski J, Melanson SM, Skolnik PR.

Clin Infect Dis. 2002 Jul 1;35(1):82-3. Epub 2002 Jun 7.

PMID:
12060879
38.

Case report: Kaposi's sarcoma: an unusual presentation.

Young AC, Mazzullo JM, Simon AR, Skolnik PR.

MedGenMed. 2001 Sep 28;3(4):8.

39.

CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection.

Chen G, Shankar P, Lange C, Valdez H, Skolnik PR, Wu L, Manjunath N, Lieberman J.

Blood. 2001 Jul 1;98(1):156-64.

PMID:
11418475
40.

Central nervous system aspergillosis in patients with human immunodeficiency virus infection. Report of 6 cases and review.

Mylonakis E, Paliou M, Sax PE, Skolnik PR, Baron MJ, Rich JD.

Medicine (Baltimore). 2000 Jul;79(4):269-80. Review.

41.

NF-kappa B modulates TNF-alpha production by alveolar macrophages in asymptomatic HIV-seropositive individuals.

Mathys JM, Melanson SM, Schiffer-Alberts DJ, Ioannidis JP, Koziel H, Skolnik PR.

J Immunol. 2000 Feb 1;164(3):1588-94.

42.

A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects.

Angel JB, Jacobson MA, Skolnik PR, Giordano M, Shapiro L, LeBeaut A, Greaves W, Fuchs AC.

AIDS. 2000 Nov 10;14(16):2503-8.

PMID:
11101061
43.

Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy.

Shevitz AH, Knox TA, Spiegelman D, Roubenoff R, Gorbach SL, Skolnik PR.

AIDS. 1999 Jul 30;13(11):1351-7.

PMID:
10449288
44.

Effect of a single bout of acute exercise on plasma human immunodeficiency virus RNA levels.

Roubenoff R, Skolnik PR, Shevitz A, Snydman L, Wang A, Melanson S, Gorbach S.

J Appl Physiol (1985). 1999 Apr;86(4):1197-201.

45.

The effect of protease inhibitors on weight and body composition in HIV-infected patients.

Silva M, Skolnik PR, Gorbach SL, Spiegelman D, Wilson IB, Fernández-DiFranco MG, Knox TA.

AIDS. 1998 Sep 10;12(13):1645-51.

PMID:
9764784
46.

Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team.

Mitsuyasu RT, Skolnik PR, Cohen SR, Conway B, Gill MJ, Jensen PC, Pulvirenti JJ, Slater LN, Schooley RT, Thompson MA, Torres RA, Tsoukas CM.

AIDS. 1998 Jul 30;12(11):F103-9.

PMID:
9708399
47.

Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients.

Lieberman J, Skolnik PR, Parkerson GR 3rd, Fabry JA, Landry B, Bethel J, Kagan J.

Blood. 1997 Sep 15;90(6):2196-206.

PMID:
9310470
48.

Invasive Aspergillus sinusitis in patients with human immunodeficiency virus infection. Report of 2 cases and review.

Mylonakis E, Rich J, Skolnik PR, De Orchis DF, Flanigan T.

Medicine (Baltimore). 1997 Jul;76(4):249-55. Review.

49.

A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection.

Lee PD, Pivarnik JM, Bukar JG, Muurahainen N, Berry PS, Skolnik PR, Nerad JL, Kudsk KA, Jackson L, Ellis KJ, Gesundheit N.

J Clin Endocrinol Metab. 1996 Aug;81(8):2968-75. Erratum in: J Clin Endocrinol Metab 1996 Oct;81(10):3696.

PMID:
8768860
50.

Recurrent muscle abscesses in a patient with HIV infection: beware the Baron von Munchausen.

Wolf LE, Skolnik PR, Noble JT.

AIDS. 1996 Jun;10(6):685-7. No abstract available.

PMID:
8780830

Supplemental Content

Loading ...
Support Center